Open Access

CD44+/CD24‑ phenotype predicts a poor prognosis in triple‑negative breast cancer

  • Authors:
    • Hui Wang
    • Li Wang
    • Ying Song
    • Shuhuai Wang
    • Xu Huang
    • Qijia Xuan
    • Xinmei Kang
    • Qingyuan Zhang
  • View Affiliations

  • Published online on: September 15, 2017     https://doi.org/10.3892/ol.2017.6959
  • Pages: 5890-5898
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer stem cells are enriched in triple‑negative breast cancer (TNBC) tumor tissues, which present strong capacities of proliferation and tumorigenicity. The present study detected the distribution of cancer stem cell markers cluster of differentiation (CD)44/CD24 and analyzed the clinical outcomes of different CD44/CD24 phenotypes in patients with TNBC. Multivariate Cox regression analyses were performed with regard to the prognostic value of cancer stem cell markers CD44/CD24, aldehyde dehydrogenase 1 and other baseline clinical characteristics, including tumor size, lymph node involved, adjuvant chemotherapy, Ki‑67, breast cancer susceptibility gene 1, cellular tumor antigen p53, vimentin and basal‑like status. The multivariate analyses showed that three of these factors, CD44/CD24 phenotype, basal‑like status and number of lymph nodes involved, had an impact on overall survival. Furthermore, patients with CD44+/CD24‑ phenotype, basal‑like tumors and ≥4 lymph nodes involved had a significantly worse prognosis. The expression of CD44 and CD24 was detected by double‑staining immunohistochemistry, which can locate cancer stem cells individually. Overall, the present results indicated that CD44/CD24 status evaluated by double‑staining immunohistochemistry constitutes an independent prognostic factor for TNBC.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 14 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang H, Wang L, Song Y, Wang S, Huang X, Xuan Q, Kang X and Zhang Q: CD44+/CD24‑ phenotype predicts a poor prognosis in triple‑negative breast cancer. Oncol Lett 14: 5890-5898, 2017
APA
Wang, H., Wang, L., Song, Y., Wang, S., Huang, X., Xuan, Q. ... Zhang, Q. (2017). CD44+/CD24‑ phenotype predicts a poor prognosis in triple‑negative breast cancer. Oncology Letters, 14, 5890-5898. https://doi.org/10.3892/ol.2017.6959
MLA
Wang, H., Wang, L., Song, Y., Wang, S., Huang, X., Xuan, Q., Kang, X., Zhang, Q."CD44+/CD24‑ phenotype predicts a poor prognosis in triple‑negative breast cancer". Oncology Letters 14.5 (2017): 5890-5898.
Chicago
Wang, H., Wang, L., Song, Y., Wang, S., Huang, X., Xuan, Q., Kang, X., Zhang, Q."CD44+/CD24‑ phenotype predicts a poor prognosis in triple‑negative breast cancer". Oncology Letters 14, no. 5 (2017): 5890-5898. https://doi.org/10.3892/ol.2017.6959